GLP-1 Therapies Research,
what lands in your inbox each week:
- 📚7 fresh studies
- 📝plain-language summaries
- ✅direct links to original studies
- 🏅top journal indicators
- 📅weekly delivery
- 🧘♂️always free
some of our latest newsletters:
(select one to read it below)
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
The GLP-1 revolution continues to reshape medicine, but new research reveals some concerning side effects hiding in the data. This week's studies paint a complex picture of these blockbuster drugs.
👁️ Semaglutide Users Face Dramatically Higher Risk of Sudden Vision Loss
Analysis of over 30 million FDA adverse event reports found Wegovy (high-dose semaglutide) linked to 75 times higher odds of ischemic optic neuropathy compared to other drugs, while Ozempic showed 19 times higher odds
Men faced even greater risk than women, with 116 times higher odds in the analysis, and the vision-threatening condition can cause permanent blindness
The dose-dependent pattern suggests higher semaglutide doses may carry substantially greater eye risks, though the absolute risk remains low
Why it matters: This represents one of the strongest safety signals yet identified for GLP-1 drugs, potentially affecting millions of users who may be unaware of this rare but serious risk.
Key Findings
📊 Digital Nudges Boost Healthy Behaviors in GLP-1 Users
Simple digital prompts plus 2-minute videos increased expectations to adopt healthy behaviors by 0.30-0.77 standard deviations immediately after exposure in 5,054 GLP-1 users
Storytelling videos outperformed educational videos across 7 of 8 healthy behaviors, and effects persisted for 2 weeks
Participants receiving storytelling videos also reduced sugar-sweetened beverage consumption compared to controls
🔬 Tirzepatide Dominates Weight Loss Rankings
Meta-analysis of 21 trials involving 7,024 participants found 78.5% of people on GLP-1 drugs achieved weight loss versus just 26.5% on placebo
Tirzepatide ranked highest with 91.2% probability of being the most effective, followed by semaglutide at 85.4%
The drugs increased odds of weight loss by 11-fold compared to placebo across studies
Implications
GLP-1 drugs continue proving their remarkable efficacy for weight loss and metabolic health, but emerging safety signals around vision loss highlight the need for careful patient monitoring and informed consent as these medications become mainstream treatments.
Science is the only real news.
The rest is just drama 📰
And nowadays, we see that drama everywhere.
Drama sells ads, ads sell products, and my attention sells to the highest bidder.
Drama media is junk food for the mind.
A quick rush, hard to avoid, but little nutritional value.
The brain wants broccoli 🧠🥦
And look, it's not that science never makes the news.
But think about when it does—does the news really understand the science it reports on?
Like it or not, AI exists now.
And it happens to be a huge science nerd… 🔭🤖
…with a superpower…
...unlike an average science nerd, AI can explain it simply.
I built OpenScience to make the constant stream of new studies accessible to anyone.
To free science from academic jargon and tiny-fonted PDFs.
OpenScience is a weekly newsletter of 7 compelling studies from the past week in the topic of your choice.
Made simple, digestible, and delightful by AI.
Interested in CRISPR?
The latest Long Covid research?
Psychedelic medicine?
Follow the actual science, as it comes out.
Every study is linked to the original PubMed so you can verify the AI's summary yourself.
Pick a topic, get the weekly email, and give your mind the broccoli it deserves 🥦
The real-time unfolding of science is too interesting not to follow.